Analyzing Corcept Therapeutics (NASDAQ:CORT) & EOM Pharmaceutical (OTCMKTS:IMUC)

Corcept Therapeutics (NASDAQ:CORT) and EOM Pharmaceutical (OTCMKTS:IMUC) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, valuation and profitability.

Volatility & Risk

Corcept Therapeutics has a beta of 0.46, indicating that its share price is 54% less volatile than the S&P 500. Comparatively, EOM Pharmaceutical has a beta of 0.05, indicating that its share price is 95% less volatile than the S&P 500.

Earnings and Valuation

This table compares Corcept Therapeutics and EOM Pharmaceutical”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corcept Therapeutics	$716.08 million	12.97	$141.21 million	$1.13	78.01
EOM Pharmaceutical	N/A	N/A	-$1.89 million	N/A	N/A

Corcept Therapeutics has higher revenue and earnings than EOM Pharmaceutical.

Institutional and Insider Ownership

93.6% of Corcept Therapeutics shares are owned by institutional investors. 20.8% of Corcept Therapeutics shares are owned by company insiders. Comparatively, 3.3% of EOM Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for Corcept Therapeutics and EOM Pharmaceutical, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corcept Therapeutics	1	1	5	0	2.57
EOM Pharmaceutical	0	0	0	0	0.00

Corcept Therapeutics presently has a consensus price target of $135.25, suggesting a potential upside of 53.43%. Given Corcept Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Corcept Therapeutics is more favorable than EOM Pharmaceutical.

Profitability

This table compares Corcept Therapeutics and EOM Pharmaceutical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Corcept Therapeutics	18.51%	20.10%	16.20%
EOM Pharmaceutical	N/A	N/A	N/A

Summary

Corcept Therapeutics beats EOM Pharmaceutical on 11 of the 11 factors compared between the two stocks.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

About EOM Pharmaceutical

Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.